Efficacy of Sr-89 for Differentiated Thyroid Cancer With Bone Metastases

• Status: Not yet recruiting
• Trial end date: 2025-07-13
• Target enrollment: 0
• Participant gender: All

Summary

Using sensitive markers (such as thyroglobulin, etc) to evaluate the efficacy of strontium-89 chloride (Sr-89) in differentiated thyroid cancer with bone metastases with an aim to breaking out of its palliation effect for bone pain.

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Peking Union Medical College Hospital

Criteria

Inclusion Criteria:

• Patients of differentiated thyroid cancer

• Positive uptake by bone metastases on bone scan

• Planing to have Sr-89 treatment

Exclusion Criteria:

• Having received treatment for bone metastases within one month of the study (such as radiotherapy, surgery, targeted therapy, chemotherapy, etc., among which denosumab and bisphosphate were allowed as basic treatment)

• Having received radioactive iodine therapy within half a year before the study

• There are bone related events, such as fracture, spinal cord compression, etc.